Oscient reiterated by JMP at strong buy

Oscient Pharmaceuticals Inc. was reiterated by JMP Securities analyst Adam Cutler at a strong buy rating with a price target on the stock of $6 per share. JMP believes the combination of Factive sales, Testim revenue and a future co-promotion partnership for Factive should draw investor attention and drive appreciation in Oscient shares throughout 2005. Oscient shares Tuesday climbed $0.11, or 4.06%, to close at $2.69 on volume of 256,604 shares versus the three-month running average of 633,548 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.